Medical disclaimer. This page is for tracking and education only. It is not medical advice and it never recommends doses. Talk with your prescriber or care team before you change, lower, or stop any medication. Ozempic, Wegovy, Mounjaro, and Zepbound are named only to describe what readers search for.
A weekly 1 to 5 check-in
The app will let you rate appetite each week on a simple 1 to 5 scale, from quiet to loud. Some people use that check-in to notice whether food noise is steady, easing, or getting harder to ignore.
It is meant for tracking, not judging. A small change in appetite can be easier to see when you have several weeks of notes in one place.
If eating feels hard, talk with a clinician.
Spotting a change
When appetite shifts, it can help to look at the whole week, not one meal or one day. The app is designed to show trends alongside your other notes, so you can connect the check-in with body weight trends, protein and fiber goals, or strength sessions if you choose to log them.
That kind of pattern may be useful when food noise returning is the question you want to watch over time. In SURMOUNT-4, adults who had completed 36 weeks of tirzepatide and then switched to placebo gained 14.0% of body weight from week 36 to week 88, while those who continued tirzepatide lost a further 5.5%.
What the app suggests and what it leaves to your care team
The app will not tell you what to do with your medication, and it will not suggest a dose, a taper, a stop date, or a start date. Those decisions belong to your prescriber or care team.
It may prompt you to notice that appetite has changed, then save that record so you can discuss it if needed. It also keeps the medical side clear: tracking only, with a built-in disclaimer.
If food feels harder to manage, or if you are unsure what a change means, bring the pattern to your care team.
Related reading
Join the iOS waitlist from Get the app.
Key facts
- In SURMOUNT-4 (JAMA 2024), from week 36 to week 88 people switched to placebo gained 14.0% of body weight, while those who continued tirzepatide lost a further 5.5%. Source
Sources
Last updated: